Literature DB >> 26649157

Application of single-layer mucosa-to-mucosa pancreaticojejunal anastomosis in pancreaticoduodenectomy.

Bing-Yang Hu1, Jian-Jun Leng1, Tao Wan1, Wen-Zhi Zhang1.   

Abstract

AIM: To investigate the simplicity, reliability, and safety of the application of single-layer mucosa-to-mucosa pancreaticojejunal anastomosis in pancreaticoduodenectomy.
METHODS: A retrospective analysis was performed on the data of patients who received pancreaticoduodenectomy completed by the same surgical group between January 2011 and April 2014 in the General Hospital of the People's Liberation Army. In total, 51 cases received single-layer mucosa-to-mucosa pancreaticojejunal anastomosis and 51 cases received double-layer pancreaticojejunal anastomosis. The diagnoses of pancreatic fistula and clinically relevant pancreatic fistula after pancreaticoduodenectomy were judged strictly by the International Study Group on pancreatic fistula definition. The preoperative and intraoperative data of these two groups were compared. χ(2) test and Fisher's exact test were used to analyze the incidences of pancreatic fistula, peritoneal catheterization, abdominal infection and overall complications between the single-layer anastomosis group and double-layer anastomosis group. Rank sum test were used to analyze the difference in operation time, pancreaticojejunal anastomosis time, postoperative hospitalization time, total hospitalization time and hospitalization expenses between the single-layer anastomosis group and double-layer anastomosis group.
RESULTS: Patients with grade A pancreatic fistula accounted for 15.69% (8/51) vs 15.69% (8/51) (P = 1.0000), and patients with grades B and C pancreatic fistula accounted for 9.80% (5/51) vs 52.94% (27/51) (P = 0.0000) in the single-layer and double-layer anastomosis groups. Although there was no significant difference in the percentage of patients with grade A pancreatic fistula, there was a significant difference in the percentage of patients with grades B and C pancreatic fistula between the two groups. The operation time (220.059 ± 60.602 min vs 379.412 ± 90.761 min, P = 0.000), pancreaticojejunal anastomosis time (17.922 ± 5.145 min vs 31.333 ± 7.776 min, P = 0.000), postoperative hospitalization time (18.588 ± 5.285 d vs 26.373 ± 15.815 d, P = 0.003), total hospitalization time (25.627 ± 6.551 d vs 33.706 ± 15.899 d, P = 0.002), hospitalization expenses (116787.667 ± 31900.927 yuan vs 162788.608 ± 129732.500 yuan, P = 0.001), as well as the incidences of pancreatic fistula [13/51 (25.49%) vs 35/51 (68.63%), P = 0.0000], peritoneal catheterization [0/51 (0%) vs 6/51 (11.76%), P = 0.0354], abdominal infection [1/51 (1.96%) vs 11/51 (21.57%), P = 0.0021], and overall complications [21/51 (41.18%) vs 37/51 (72.55%), P = 0.0014] in the single-layer anastomosis group were all lower than those in the double-layer anastomosis group.
CONCLUSION: Single-layer mucosa-to-mucosa pancreaticojejunal anastomosis appears to be a simple, reliable, and safe method. Use of this method could reduce the postoperative incidence of complications.

Entities:  

Keywords:  Pancreatic fistula; Pancreaticoduodenectomy; Pancreaticojejunal anastomosis

Year:  2015        PMID: 26649157      PMCID: PMC4663388          DOI: 10.4240/wjgs.v7.i11.335

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  31 in total

1.  History of pancreaticojejunostomy in pancreaticoduodenectomy: development of a more reliable anastomosis technique.

Authors:  A Kakita; M Yoshida; T Takahashi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

2.  Late pancreaticojejunostomy stent migration and hepatic abscess after Whipple procedure.

Authors:  Masoud Rezvani; Paul V O'Moore; Christopher M Pezzi
Journal:  J Surg Educ       Date:  2007 Jul-Aug       Impact factor: 2.891

Review 3.  Preoperative biliary drainage for obstructive jaundice.

Authors:  Qin Wang; Kurinchi Selvan Gurusamy; He Lin; Xiaodong Xie; Chaohua Wang
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

4.  Determinants of complications in pancreaticoduodenectomy.

Authors:  B Topal; R Aerts; T Hendrickx; S Fieuws; F Penninckx
Journal:  Eur J Surg Oncol       Date:  2006-12-04       Impact factor: 4.424

5.  Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula.

Authors:  John W Lin; John L Cameron; Charles J Yeo; Taylor S Riall; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

6.  Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy.

Authors:  Markus W Büchler; Markus Wagner; Bruno M Schmied; Waldemar Uhl; Helmut Friess; Kaspar Z'graggen
Journal:  Arch Surg       Date:  2003-12

7.  Conventional versus binding pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial.

Authors:  Shu You Peng; Jian Wei Wang; Wan Yee Lau; Xiu Jun Cai; Yi Ping Mou; Ying Bin Liu; Jiang Tao Li
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Biochemical markers predict morbidity and mortality after pancreaticoduodenectomy.

Authors:  Jordan M Winter; John L Cameron; Charles J Yeo; Babatunde Alao; Keith D Lillemoe; Kurtis A Campbell; Richard D Schulick
Journal:  J Am Coll Surg       Date:  2007-03-27       Impact factor: 6.113

9.  Prospective randomized pilot trial comparing closed suction drainage and gravity drainage of the pancreatic duct in pancreaticojejunostomy.

Authors:  Seung Eun Lee; Young-Joon Ahn; Jin-Young Jang; Sun-Whe Kim
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009

Review 10.  The challenge of pancreatic anastomosis.

Authors:  Axel Kleespies; Markus Albertsmeier; Firas Obeidat; Hendrik Seeliger; Karl-Walter Jauch; Christiane J Bruns
Journal:  Langenbecks Arch Surg       Date:  2008-04-01       Impact factor: 3.445

View more
  1 in total

1.  Risk factors for postoperative pancreatic fistula: Analysis of 539 successive cases of pancreaticoduodenectomy.

Authors:  Bing-Yang Hu; Tao Wan; Wen-Zhi Zhang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.